ASTELLAS ADR Aktie

 

MELVILLE, N.Y., June 17, 2025 /PRNewswire/ -- Nikon Instruments Inc. (Nikon), a wholly owned subsidiary of Nikon Corporation, and Astellas Innovation Management LLC ("Astellas"), a wholly owned subsidiary of Astellas Pharma Inc., have entered a strategic collaboration to support......

This collaboration is expected to strengthen the country's role as an international hub for drug discovery. This new support is part of several programmes under the Medical Innovation The post MRI and Astellas to support Japanese drug-discovery startups appeared first on Pharmaceutical Business review....

TOKYO (dpa-AFX) - Astellas Pharma and Mitsubishi Research Institute or MRI have agreed to work together to help drug-discovery startups in Japan expand globally. Their goal is to make Japan a stro......

Accelerating the Growth of Globally Active Drug-Discovery Startups from Japan TOKYO, June 13, 2025 /PRNewswire/ -- Mitsubishi Research Institute, Inc. ("MRI") and Astellas Pharma Inc. ("Astellas") today announced that they have agreed on a memorandum of understanding to provide......

Vault CRM will support Astellas' commercial agility and execution PLEASANTON, Calif., June 4, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Astellas has chosen Veeva Vault CRM globally and Veeva China CRM for China. "At Astellas, we discover and deliver transformative......

- Agreement grants Astellas exclusive worldwide rights (excluding China's mainland, Hong Kong, Macao and Taiwan region) to develop and commercialize XNW27011 - - XNW27011 has demonstrated encouraging monotherapy efficacy in an ongoing Phase 1/2 study of patients with solid tumors,......

Building on a successful inaugural year, the initiative sponsored by Astellas' Patient Centricity team continues to connect individuals with vital resources and support from patient advocacy organizations NORTHBROOK, Ill., May 28, 2025 /PRNewswire/ -- Astellas Patient Centricity is......

Here is how Astellas Pharma Inc. (ALPMY) and AtriCure (ATRC) have performed compared to their sector so far this year....

NEW YORK CITY (dpa-AFX) - Astellas Pharma Inc. (ALPMY) and Pfizer Inc. (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ARCHES study, reporting a five-year......

Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, treatment with XTANDI (enzalutamide) plus ADT was associated with a 66% probability of survival......

Both companies have earned a year-long opportunity for access to a distinguished life-science incubator in San Francisco along with the invaluable expertise provided by Astellas to advance their research endeavors Award helps biotech startups accelerate early research efforts NORTHBROOK,......

16 abstracts, including two oral presentations, feature new clinical data from Astellas' oncology portfolio TOKYO, May 19, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will present 16 abstracts featuring new data across its approved......

Astellas Pharma (ALPMY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term....

The global pharmaceutical industry is grappling with an uncertain outlook, amid President Donald Trump's plans to cut US prescription drug prices and impose tariffs on pharma imports. Astellas Pharma is among the Japanese drug makers that depends on the US for a large chunk of sales. CEO Naoki Okamura spoke to Bloomberg TV in Tokyo on May 7th about the impact of Trump's tariffs, and the firm's engagement with activist investor Farallon Capital Management. (Source: Bloomberg)...

TOKYO, May 7, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that during a meeting of its Board of Directors held today, it decided a change in Directors as outlined below. The appointment of Andreas Busch and Mark......

ARVO and RWC abstracts feature analyses on biomarkers, mechanism of disease, patient experience and other data from IZERVAY™ (avacincaptad pegol intravitreal solution) pivotal studies TOKYO, May 1, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura,......

Astellas Pharma (ALPMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy)....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Partnerships to help create more todays and better tomorrows for bladder cancer patients and families BETHESDA, Md., April 15, 2025 /PRNewswire/ -- Today, the Bladder Cancer Advocacy Network (BCAN) announced its partnerships with Ferring Pharmaceuticals and the Astellas/Pfizer Alliance as......

Chromatin Bioscience: Edinburgh, Schottland (ots/PRNewswire) - Chromatin Bioscience, ein führendes Unternehmen im Bereich der Entwicklung synthetischer Promotoren und Genkontrollsysteme, freut sich, eine Kooperationsvereinbarung mit dem globalen ......